The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy

Eugenio Montini, Daniela Cesana, Manfred Schmidt, Francesca Sanvito, Cynthia C. Bartholomae, Marco Ranzani, Fabrizio Benedicenti, Lucia Sergi Sergi, Alessandro Ambrosi, Maurilio Ponzoni, Claudio Doglioni, Clelia Di Serio, Christof Von Kalle, Luigi Naldini

Research output: Contribution to journalArticle

Abstract

γ-Retroviral vectors (γRVs), which are commonly used in gene therapy, can trigger oncogenesis by insertional mutagenesis. Here, we have dissected the contribution of vector design and viral integration site selection (ISS) to oncogenesis using an in vivo genotoxicity assay based on transplantation of vector-transduced tumor-prone mouse hematopoietic stem/progenitor cells. By swapping genetic elements between γRV and lentiviral vectors (LVs), we have demonstrated that transcriptionally active long terminal repeats (LTRs) are major determinants of genotoxicity even when reconstituted in LVs and that self-inactivating (SIN) LTRs enhance the safety of γRVs. By comparing the genotoxicity of vectors with matched active LTRs, we were able to determine that substantially greater LV integration loads are required to approach the same oncogenic risk as γRVs. This difference in facilitating oncogenesis is likely to be explained by the observed preferential targeting of cancer genes by γRVs. This integration-site bias was intrinsic to γRVs, as it was also observed for SIN γRVs that lacked genotoxicity in our model. Our findings strongly support the use of SIN viral vector platforms and show that ISS can substantially modulate genotoxicity.

Original languageEnglish
Pages (from-to)964-975
Number of pages12
JournalJournal of Clinical Investigation
Volume119
Issue number4
DOIs
Publication statusPublished - Apr 1 2009

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy'. Together they form a unique fingerprint.

  • Cite this